Výsledky vyhledávání - "Anjanette Sorensen"

Abstract P1-18-30: Neoadjuvant aromatase inhibitor and pertuzumab and trastuzumab (NEOADAPT) up to one year for HR+HER2+ breast cancer: Results from a prematurely closed de-escalation study

Autor: Jizhou Ai, Ricardo H. Alvarez, Damien Mikael Hansra, Maurie Markman, Eugene R Ahn, Anjanette Sorensen

Publikováno v: Cancer Research. 80:P1-18

Background. Current standard of care for HR+HER2+ breast cancer >1cm per NCCN guidelines is chemotherapy with either trastuzumab(T) or trastuzumab and pertuzumab(TP) with anti-HER2 therapy continued for 1 year and anti-hormonal therapy for 5-10 years

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5ab5d26a5f54fe6bcc58503091aefec6
https://doi.org/10.1158/1538-7445.sabcs19-p1-18-30

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání